Company: HRTX
Filing Date: 2025-09-09
Form Type: S-3
Source: 0000950170-25-113830
Chunk: 47

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-09
Form: S-3
Chunk 47
---
 Company’s Series B Preferred Stock contained in the registration statement on Form 8-A , filed with the SEC on August 15, 2025 pursuant to Section 12 of the Exchange Act, including any amendment or report filed for the purpose of updating that description; and

any statement contained in any document incorporated by reference herein will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any additional prospectus supplements modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

We will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with this prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates. To request such materials, please contact Ira Duarte, Executive Vice President, Chief Financial Officer, at the following address or telephone number: Heron Therapeutics, Inc., 100 Regency Forest Drive, Suite 300, Cary, North Carolina 27518, (858) 251-4400. A copy of all documents that are incorporated by reference into this prospectus can also be found on our website by accessing www.herontx.com.

<div align='center'>27

LEGAL MATTERS</div>

The validity of the securities offered hereby will be passed upon for us by DLA Piper LLP (US), Short Hills, New Jersey. Additional legal matters may be passed upon for us, the Selling Stockholders or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.

<div align='center'>EXPERTS</div>

The financial statements incorporated in this Prospectus by reference to theAnnual Report on Form 10-K for the year ended December 31, 2024have been so incorporated in reliance on the report of WithumSmith+Brown, PC, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

<div align='center'>28</div>

PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution The following table sets forth an itemization of the various expenses, all of which we will pay, in connection with